SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann, M; Kleine-Weber, H; Schroeder, S; Krüger, N; Herrler, T; Erichsen, S; Schiergens, TS; Herrler, G; Wu, NH; Nitsche, A; Müller, MA; Drosten, C; Pöhlmann, S;
Cell. 2020; 181(2): 271-280.e8.
Originalarbeiten (Zeitschrift)